Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

被引：23
|
作者：
Daver, Naval
Altman, Jessica K.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James K.
Smith, Catherine C.
Schiller, Gary J.
Bradley, Terrence
Tiu, Ramon V.
Hong, Wan-Jen
Tong, Bo
Qin, Qin
Dilley, Kimberley
Perl, Alexander E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
    McCall, David
    Roth, Michael
    Mahadeo, Kris M.
    Toepfer, Laurie
    Nunez, Cesar
    Short, Nicholas J.
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney
    Yi, Joanna S.
    Cuglievan, Branko
    BLOOD ADVANCES, 2021, 5 (23) : 5215 - 5219
  • [22] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
    Fathi, Amir Tahmasb
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana E.
    Faller, Douglas V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
    Briski, Robert
    Short, Nicholas J.
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Valero, Yesid Alvarado
    Vaughan, Kenneth
    Pierce, Sherry
    Montalbano, Kathryn
    Mullin, Jillian
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2023, 142
  • [24] Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
    Short, Nicholas
    DiNardo, Courtney D.
    Daver, Naval
    Macaron, Walid
    Yilmaz, Musa
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Sasaki, Koji
    Thompson, Philip A.
    Burger, Jan A.
    Maiti, Abhishek
    Alvarado, Yesid
    Kwari, Monica
    Delumpa, Ricardo
    Thankachan, Jennifer
    Mayor, Ejiroghene
    Loiselle, Christopher
    Milton, Anna
    Banks, Glenda
    Kadia, Tapan M.
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    BLOOD, 2022, 140 : 2007 - 2009
  • [25] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [26] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Li, Huang
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BLOOD, 2023, 142
  • [27] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
    Jonas, Brian A.
    Hou, Jing-Zhou
    Roboz, Gail J.
    Alvares, Caroline L.
    Jeyakumar, Deepa
    Edwards, John R.
    Erba, Harry P.
    Kelly, Richard J.
    Roellig, Christoph
    Fiedler, Walter
    Brackman, Deanna
    Siddani, Satya R.
    Chyla, Brenda
    Hilger-Rolfe, Jacqueline
    Watts, Justin M.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
  • [28] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W. -C.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S. -S.
    Lee, J. -H.
    Pardee, T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 295 - 295
  • [29] Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
    Smith, Catherine C.
    Levis, Mark J.
    Perl, Alexander E.
    Martinelli, Giovanni
    Neubauer, Andreas
    Berman, Ellin
    Montesinos, Pau
    Baer, Maria R.
    Larson, Richard A.
    Chou, Wen-Chien
    Yokoyama, Hisayuki
    Recher, Christian
    Yoon, Sung-Soo
    Hill, Jason E.
    Rosales, Matt
    Bahceci, Erkut
    BLOOD, 2019, 134
  • [30] GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S.
    Pardee, J. Lee T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    HAEMATOLOGICA, 2019, 104 : 2 - 2
12345